Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Congresswoman has cancer; the IRS is suing a controversial doctor; and caffeine and teenagers.

2.

In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.

3.

Nuclear missile workers are contracting cancer: They blame the bases

4.

The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.

5.

Train Eyes so Myopia Doesn't Get Worse? Nurse Intervention for BP Post-Stroke


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot